Changes in the Expression of Insulin Pathway, Neutrophil Elastase and Alpha 1 Antitrypsin Genes from Leukocytes of Young Individuals with Insulin Resistance.
alpha 1 antitrypsin
insulin resistance
insulin signaling
leukocytes
neutrophil elastase
obesity
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
02
2022
accepted:
19
05
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Chronic hyperinsulinemia is a hallmark of insulin resistance that affects a diversity of cells, including leukocytes modifying the expression of some genes involved in insulin signaling. The aim of this study was to evaluate how hyperinsulinemia affects the expression of genes involved in the proximal insulin signaling pathway in leukocytes from 45 young individuals grouped: normal weight with not insulin resistance (NIR), with insulin resistance (IR) and with obesity (OB-IR). qPCR was performed to analyze the expression of insulin receptor (INSR), insulin receptor substrate 1 and 2 (IRS-1 and IRS-2), neutrophil elastase (NE), alpha 1 antitrypsin (A1AT), glucose transporters 1, 3 and 4 (GLUT-1, GLUT-3 and GLUT-4) by the 2 The mRNA expression analysis of all genes between NIR and IR individuals revealed no differences. However, when comparing NIR and IR individuals with OB-IR, an increase in NE and A1AT expression and a clear trend towards a decrease in IRS-2 expression was observed, whereas the comparison of IR and OB-IR showed a decrease in GLUT-3 expression. Overall, the correlation analysis showed that in the IR group there was a positive correlation only between NE with IRS-1 (r = 0.72, These results suggest that hyperinsulinemia and obesity are associated with changes in the expression of genes in leukocytes involved in the insulin pathway that are related to NE and A1AT.
Sections du résumé
Background
UNASSIGNED
Chronic hyperinsulinemia is a hallmark of insulin resistance that affects a diversity of cells, including leukocytes modifying the expression of some genes involved in insulin signaling.
Purpose
UNASSIGNED
The aim of this study was to evaluate how hyperinsulinemia affects the expression of genes involved in the proximal insulin signaling pathway in leukocytes from 45 young individuals grouped: normal weight with not insulin resistance (NIR), with insulin resistance (IR) and with obesity (OB-IR).
Methods
UNASSIGNED
qPCR was performed to analyze the expression of insulin receptor (INSR), insulin receptor substrate 1 and 2 (IRS-1 and IRS-2), neutrophil elastase (NE), alpha 1 antitrypsin (A1AT), glucose transporters 1, 3 and 4 (GLUT-1, GLUT-3 and GLUT-4) by the 2
Results
UNASSIGNED
The mRNA expression analysis of all genes between NIR and IR individuals revealed no differences. However, when comparing NIR and IR individuals with OB-IR, an increase in NE and A1AT expression and a clear trend towards a decrease in IRS-2 expression was observed, whereas the comparison of IR and OB-IR showed a decrease in GLUT-3 expression. Overall, the correlation analysis showed that in the IR group there was a positive correlation only between NE with IRS-1 (r = 0.72,
Conclusion
UNASSIGNED
These results suggest that hyperinsulinemia and obesity are associated with changes in the expression of genes in leukocytes involved in the insulin pathway that are related to NE and A1AT.
Identifiants
pubmed: 35757193
doi: 10.2147/DMSO.S362881
pii: 362881
pmc: PMC9215908
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1865-1876Informations de copyright
© 2022 Cruz-Pineda et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Diabetol Metab Syndr. 2020 Jan 07;12:2
pubmed: 31921359
Metabolism. 2004 Apr;53(4):495-9
pubmed: 15045698
Cell Metab. 2018 Dec 4;28(6):922-934.e4
pubmed: 30174303
Front Pharmacol. 2018 Apr 17;9:341
pubmed: 29719508
Am J Physiol Heart Circ Physiol. 2011 May;300(5):H1637-44
pubmed: 21335475
Biol Chem. 2014 Oct;395(10):1187-93
pubmed: 24854541
Diabetes Metab Syndr. 2020 Mar - Apr;14(2):83-85
pubmed: 31991297
Genes Dev. 2005 Oct 15;19(20):2435-46
pubmed: 16230533
Mol Endocrinol. 1987 Nov;1(11):759-66
pubmed: 2484715
FASEB J. 2019 Jun;33(6):7072-7083
pubmed: 30840838
Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 2):S114-7
pubmed: 7952645
Metab Syndr Relat Disord. 2018 Oct;16(8):395-405
pubmed: 30063173
Am J Physiol. 1989 Sep;257(3 Pt 1):E451-7
pubmed: 2782405
Curr Hypertens Rep. 2018 Feb 26;20(2):12
pubmed: 29480368
Metabolism. 2001 Jul;50(7):771-7
pubmed: 11436180
Diabetes Res Clin Pract. 2020 Mar;161:108050
pubmed: 32035116
Front Immunol. 2015 Jan 22;6:1
pubmed: 25657648
Diabetes. 2011 Dec;60(12):3265-70
pubmed: 21984580
Diabetes Care. 2008 Jul;31(7):1433-8
pubmed: 18594063
Physiol Rev. 2018 Oct 1;98(4):2133-2223
pubmed: 30067154
Blood Cells Mol Dis. 2002 Mar-Apr;28(2):152-9
pubmed: 12064911
Horm Mol Biol Clin Investig. 2019 May 28;39(2):
pubmed: 31136298
J Clin Invest. 1996 Jun 15;97(12):2859-65
pubmed: 8675698
J Diabetes Investig. 2019 Jan;10(1):29-31
pubmed: 30144345
Eur J Endocrinol. 2018 May;178(5):523-531
pubmed: 29535167
Physiol Rev. 1996 Oct;76(4):1109-61
pubmed: 8874496
Nat Commun. 2018 Nov 19;9(1):4863
pubmed: 30451856
PLoS One. 2013;8(3):e60673
pubmed: 23556000
Eur J Clin Invest. 2007 Apr;37(4):282-90
pubmed: 17373964
Cytometry A. 2005 Mar;64(1):27-33
pubmed: 15688355
Genome Res. 2016 Dec;26(12):1627-1638
pubmed: 27934696
J Diabetes. 2010 Sep;2(3):180-93
pubmed: 20923483
Cell Metab. 2017 Aug 1;26(2):310-323
pubmed: 28712655
Am J Physiol Lung Cell Mol Physiol. 2016 May 1;310(9):L837-45
pubmed: 26919895
J Leukoc Biol. 2008 Oct;84(4):949-57
pubmed: 18577716
Am J Med. 1999 Nov;107(5):450-5
pubmed: 10569299
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
J Immunol. 2017 Mar 1;198(5):1910-1920
pubmed: 28115529
PLoS One. 2015 May 13;10(5):e0125238
pubmed: 25970186
Obes Rev. 2014 Sep;15(9):697-708
pubmed: 25059108
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):62-67
pubmed: 30641777
Diabetologia. 1997 Jul;40 Suppl 2:S2-17
pubmed: 9248696
FEBS Lett. 1998 Oct 9;436(3):301-3
pubmed: 9801136
J Biol Chem. 1995 Oct 20;270(42):24678-81
pubmed: 7559581
BMC Med. 2020 Aug 21;18(1):224
pubmed: 32819363
PLoS One. 2017 Jan 20;12(1):e0170533
pubmed: 28107454
Infect Immun. 2012 Dec;80(12):4409-16
pubmed: 23027538
Cell Rep. 2019 Mar 19;26(12):3429-3443.e3
pubmed: 30893613
J Leukoc Biol. 2022 Jan;111(1):197-208
pubmed: 33724523
Nat Med. 2012 Sep;18(9):1407-12
pubmed: 22863787
Ann Med. 2013 May;45(3):242-53
pubmed: 22834949
J Immunol. 2019 Mar 15;202(6):1786-1797
pubmed: 30718296
Front Immunol. 2020 Nov 18;11:583385
pubmed: 33312173
Lipid Insights. 2013 Apr 01;6:1-11
pubmed: 25278764
Mol Biol Rep. 2018 Oct;45(5):1245-1252
pubmed: 30056589
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Cell Metab. 2013 Apr 2;17(4):534-48
pubmed: 23562077
Endocr J. 1994 Dec;41(6):737-41
pubmed: 7704100
ISRN Mol Biol. 2012 Oct 17;2012:856987
pubmed: 27335671
Exp Neurol. 2006 Mar;198(1):48-53
pubmed: 16337941
Am J Physiol Endocrinol Metab. 2002 Sep;283(3):E413-22
pubmed: 12169433
Anal Biochem. 1987 Apr;162(1):156-9
pubmed: 2440339
Lipids Health Dis. 2015 Sep 29;14:121
pubmed: 26415887